The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has issued a new order on November 4, 2025, revising the ceiling prices of several key medicines under the Drugs (Prices Control) Order, 2013 (DPCO 2013). The updated list includes Riboflavin tablets (10mg), Peritoneal dialysis solution, Ethyl alcohol (70%), and Human Normal Immunoglobulin in various strengths.
The revised ceiling prices range from 0.22 to 478.57 rupees per unit, excluding Goods and Services Tax (GST). Manufacturers selling these scheduled formulations must ensure that their prices do not exceed the fixed ceiling price plus applicable GST. If a manufacturer’s existing price is lower than the new ceiling, it must remain unchanged. Manufacturers are also required to submit updated price lists in Form-V through the Integrated Pharmaceutical Database Management System (IPDMS) and share copies with the State Drug Controllers and dealers. Retailers must display the price lists prominently for public access.
The order also mandates quarterly production and sales returns in Form-III and prior intimation for any discontinuation of products. Non-compliance with these provisions will result in the recovery of overcharged amounts, along with interest, under the Essential Commodities Act, 1955. The revised prices replace previous price orders to maintain uniformity, affordability, and transparency in pharmaceutical pricing across India. This move by NPPA ensures fair pricing of essential medicines, strengthens consumer protection, and reinforces government efforts to make vital drugs accessible and affordable for all citizens.